BioXcel Therapeutics (BTAI) Retained Earnings (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Retained Earnings of -$732.8 million for Q1 2026, down 11.46% year-over-year from -$827.6 million in Q1 2025, and down 217.33% quarter-over-quarter from $624.6 million in Q4 2025.
BioXcel Therapeutics (BTAI) Retained Earnings (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Retained Earnings history runs 10 years deep, the most recent figure standing at -$732.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 11.46% year-over-year to -$732.8 million; the TTM figure through Mar 2026 stood at -$732.8 million (down 11.46% YoY), while the FY2025 annual figure was $624.6 million, up 12.12% from the prior year.
- Retained Earnings for Q1 2026 stood at -$732.8 million, down from $624.6 million in the prior quarter.
- The five-year high for Retained Earnings was $624.6 million in Q4 2025, with the low at -$732.8 million in Q1 2026.
- The 5-year median for Retained Earnings is $479.2 million (2022), against an average of $40.3 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings surged 385.2% in 2022, then plunged 227.79% in 2025.
- BioXcel Therapeutics' Retained Earnings stood at $488.3 million in 2022, then sank by 220.95% to -$590.6 million in 2023, then jumped by 194.32% to $557.0 million in 2024, then rose by 12.12% to $624.6 million in 2025, then tumbled by 217.33% to -$732.8 million in 2026.
- Business Quant data shows BTAI's Retained Earnings at -$732.8 million in Q1 2026, $624.6 million in Q4 2025, and -$707.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 3.75 Bn |
| 10 | BioXcel Therapeutics | 24.29 Mn | 24.29 Mn | 160,000.00 | -747.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -747.50 Mn |
| Mar 31, 2026 | -732.79 Mn |
| Dec 31, 2025 | 624.56 Mn |
| Sep 30, 2025 | -707.55 Mn |
| Jun 30, 2025 | -676.64 Mn |
| Mar 31, 2025 | -657.45 Mn |
| Dec 31, 2024 | 557.05 Mn |
| Sep 30, 2024 | 553.66 Mn |
| Jun 30, 2024 | -625.69 Mn |
| Mar 31, 2024 | 544.99 Mn |
| Dec 31, 2023 | -590.60 Mn |
| Sep 30, 2023 | -568.34 Mn |
| Jun 30, 2023 | 523.69 Mn |
| Mar 31, 2023 | 517.32 Mn |
| Dec 31, 2022 | 488.29 Mn |
| Sep 30, 2022 | 483.70 Mn |
| Jun 30, 2022 | 479.16 Mn |
| Mar 31, 2022 | 471.25 Mn |
| Dec 31, 2021 | 467.43 Mn |
| Sep 30, 2021 | -219.66 Mn |